Literature DB >> 1913805

Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.

M Del Val1, H J Schlicht, T Ruppert, M J Reddehase, U H Koszinowski.   

Abstract

Processing of endogenously synthesized proteins generates short peptides that are presented by MHC class I molecules to CD8 T lymphocytes. Here it is documented that not only the sequence of the presented peptide but also the residues by which it is flanked in the protein determine the efficiency of processing and presentation. This became evident when a viral sequence of proven antigenicity was inserted at different positions into an unrelated carrier protein. Not different peptides, but different amounts of the antigenic insert itself were retrieved by isolation of naturally processed peptides from cells expressing the different chimeric proteins. Low yield of antigenic peptide from an unfavorable integration site could be overcome by flanking the insert with oligo-alanine to space it from disruptive neighboring sequences. Notably, the degree of protection against lethal virus disease related directly to the amount of naturally processed antigenic peptide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913805     DOI: 10.1016/0092-8674(91)90037-y

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  103 in total

1.  A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.

Authors:  U Reusch; W Muranyi; P Lucin; H G Burgert; H Hengel; U H Koszinowski
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Immune response and virus population composition: HIV as a case study.

Authors:  Gal Almogy; Netta Cohen; Sabine Stöcker; Lewi Stone
Journal:  Proc Biol Sci       Date:  2002-04-22       Impact factor: 5.349

4.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

6.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

7.  Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous beta 2-microglobulin.

Authors:  J D Smith; W R Lie; J Gorka; N B Myers; T H Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor.

Authors:  R Thäle; P Lucin; K Schneider; M Eggers; U H Koszinowski
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Authors:  L M Mylin; R H Bonneau; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.